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Summary We carried out a comparison of three commonly used mucin markers, CA549, CA15.3 and MCA.
Serum samples from 184 healthy women and 237 patients with primary breast cancer were evaluated. The
markers were measured using commercially available immunometric assays. Like CA15.3 and MCA, CA549
was significantly associated with tumour size and lymph node status, being an effective indicator of tumour
bulk. CA549 was significantly correlated with both CA15.3 and MCA. Positive/negative concordance rate was
very good (93.7%) between CA549 and MCA. Conversely, CA15.3 was positive and CA549 negative in 20.4%
of cases. Axillary status was not significantly different in the latter group of patients and in cases in which
CA15.3 and CA549 showed concordant results. From the present findings we draw the following major
conclusions:
1. CA549 and MCA are highly correlated and their association should not provide additional information;
however, they should not be considered interchangeable since they may behave differently in individual
cases.
2. CA549 and CA15.3, although well correlated, are discordant in a significant number of cases. Longi-
tudinal studies are needed to verify the usefulness of the association between the two markers.
3. The three evaluated mucin markers are not interchangeable in individual patients; if a patient is
monitored with a marker, she should be followed up with the same marker.
Serum tumour markers are currently used in patients with
breast cancer (Bates et al., 1985; von Kleist et al., 1988;
Gion, 1992). Although they provide reliable information on
disease progression during follow-up, their real impact on the
prognosis ofpatients is still controversial because of the poor
effectiveness of the available treatments for metastatic disease
(Zwaveling et al., 1987; Stierer et al., 1989). The majority of
investigators agree on two points: (1) the routine use of
tumour markers should be limited to one or two; (2) the
first-line tumour marker should be an antigen related to the
mucin family (von Kleist et al., 1993).
CA15.3, MCA and CA549 are three among the most
studied tumour markers of the routinely available mucin-
associated antigens. CA15.3 is detected by a two-site
immunoradiometric assay (Tobias et al., 1985) devised using
two monoclonal antibodies: DF3, raised against a membrane
fraction of breast cancer tissue, and 115/D8, raised against
milk fat globule membrane (Hilkens et al., 1984; Kufe et al.,
1984).
MCA is measured using a two-site enzyme immunoassay
method in which a single monoclonal antibody (bl2) raised
against the breast cancer cell line ZR-75-1 is used (Stiihli et
al., 1985, 1988).
Carbohydrate antigen 549 (CA549), identified in 1987, is
expressed in a circulating cancer-associated mucin that is
recognised by the monoclonal antibody BC4E549, raised
against purified membranes from the T417 human breast
tumour cells. An immunoradiometric assay was developed by
Bray et al. (1987) in which BC4E549 antibody was used as
the tracer antibody associated with a second monoclonal
antibody raised against milk fat globule membrane
(BC4N154) as catcher antibody. Several clinical studies
showed its possible clinical usefulness in patients with breast
cancer (Bray et al., 1988; Demers et al., 1988; Bhargava et
al., 1989; Bagni et al., 1990; Soletormos et al., 1990, 1992;
Yerna et al., 1990; Cooper et al., 1992).
It remains to be determined if there are any more effective
members among these mucin-associated antigens. It is worth
noting that the majority of the evaluations were carried out
categorising the markers as positive or negative. We could
demonstrate that significant variations in CA15.3 serum
levels may occur when still below the positive/negative
threshold level (Gion et al., 1991, 1993). The aim of the
present investigation was therefore to compare CA549 with
both CA15.3 and MCA in patients with breast cancer and in
healthy subjects, evaluating the markers as both continuous
variables and positive/negative categories. The same serum
specimens were used for the determination of CA549,
CA15.3 and MCA.
Patients and methods
Serum samples were collected between 1986 and 1988 from
184 apparently healthy women (median age 50 years, range
34-78) and 237 patients with primary breast cancer before
surgery (median age 60 years, range 29-88) stages I-III.
Serum samples were stored frozen in multiple fractions until
assay. Inclusion criteria were:
1. no clinical or laboratory evidence of benign liver, pan-
creas, ovary and kidney diseases;
2. no radiotherapy, chemotherapy or endocrine manipula-
tion before the surgery in patients with primary breast
cancer.
Patient staging was carried out according to the UICC
criteria. Histological typing was done following the WHO
classification.
Oestrogen (ER) and progesterone receptors (PR) were
measured in high-speed cytosol using a radioligand-binding
assay set up according to the EORTC (European Organiza-
tion for Research and Treatment of Cancer) standardisation
criteria (EORTC, 1973).
CA549 was measured using the commercially available
IRMA method (Hybri-BREScanCA549, Hybritech Europe,
Liege, Belgium). Briefly, 201 l of unknown serum samples
and calibrators was incubated with 300ftl of assay buffer and
BC4N154 antibody-coated beads for 2 h (with continuous
shaking on a rotator). The beads were then washed twice and
200 ,sl of '25I-labelled BC4E459 monoclonal antibody was
dispensed. After a 2 h incubation at room temperature the
beads were washed and the bound radioactivity counted.
CA549 in a limited number of cases (85) was also
measured with an enzyme immunoassay (CA549-BREScan
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TANDEM-E, Hybritech Europe, Liege, Belgium) used ac-
cording to the manufacturer's instructions and the results
were compared with those obtained by IRMA.
CA549 performance characteristics were validated before
routine use of the assay. Assay precision was evaluated using
serum pools as well as the control material provided by the
manufacturer. A precision profile set-up using both cali-
brators and serum samples was also carried out. Linearity
was assessed by diluting a serum sample with high antigen
levels using the 'O' standard.
CA15.3 was measured with a two-site IRMA method
(ELSA-CA15.3, CIS Biointernational, Gif-sur-Yvette,
France); MCA was determined with an EIA (Hoffman La
Roche, Basle, Switzerland). Both were measured following
the manufacturer's instructions. The performance character-
istics and validation of both MCA and CA15.3 have been
previously described (Bombardieri et al., 1989; Gion et al.,
1991).
Statistical analysis
Data were evaluated using the Kruskal-Wallis test, the Wil-
coxon test, the Fisher exact test, linear regression and Spear-
man correlation. All computations were carried out using the
BMDP statistical software package.
Results
CA549performance characteristics
Precision Using serum pools, the intra-assay coefficient of
variation was lower than 7.0% and the inter-assay CV was
lower than 10.0%. These results were confirmed using con-
trol material provided by the manufacturer (intra-assay CV
lower than 8%, inter-assay CV lower than 11%). The pre-
cision profile showed that the kit precision is within 10% in a
dose interval ranging from 1OU ml-' to the higher calibra-
tion point of the standard curve (73 Uml').
Linearity The dilution results showed a good linearity up to
a 1:32 dilution factor with the recovery ranging from 94 to
100%.
Analytical sensitivity The lower detectable level of the
method was defined as the dose corresponding to the c.p.m.
which results from the mean of 20 replicates of standard 'O'
plus three standard deviations. It was 0.2 U ml' with the
IRMA method and 0.4 U ml-' with the EIA method.
The performance characteristics of the CA549 assay kit
were similar to those found by other groups (Cooper et al.,
1992).
CA549 IRMA vs EIA
CA549 was measured in 85 serum samples with both IRMA
and EIA assay methods. The results obtained with the two
methods showed a close correlation, as is shown in Figure 1
(EIA = 0.95 IRMA + 0.89, r = 0.994). The analysis of indi-
vidual cases confirmed that no discrepancies in the clinical
classification of patients were identifiable between the results
of EIA and IRMA (data not shown).
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Figure 1 Correlation between IRMA and EIA CA549 assays
(EIA = 0.95 IRMA + 0.89, r = 0.994, n = 85).
Healthy subjects CA549 in healthy subjects ranged from 1.6
to 20.1 U ml-' (mean 6.7 ± 3.5 s.d.). No significant variation
in antigen concentration was found in relation to age
(patients were subdivided into groups spanning 10 years) or
to menopausal status, although the antigen levels tended to
be more widely scattered in older women. The antigen dist-
ribution was not significantly different from Gaussian
(Kolmogorov-Smirnov test, P>0.1) in the whole group as
well as in the subgroups selected according to menopausal
status. Therefore, several possible cut-off points were cal-
culated using parametric criteria (Table I). From the control
group examined in the present investigation different cut-off
points could be suggested for pre- and post-menopausal
women, as previously shown for CA15.3 and MCA (Bombar-
dieri et al., 1989; Gion et al., 1991).
Primary breast cancer As opposed to healthy subjects,
CA549 in patients with primary breast cancer showed a
distribution that is significantly different from Gaussian
(Kolmogorov-Smirnov test, z = 1.920, P = 0.001). CA549
concentration in the whole group of patients with breast
cancer was not significantly different from that found in the
control group. When subdividing patients according to
clinical stage, CA549 levels were significantly higher in stage
III cancer patients (median 7.1 U ml', interquartile
2.6-13.3 U ml') than in normal subjects (median
6.1 U mlh ', interquartile 3.9-8.5 U mlh ', P<0.01), while the
Table I CA549 serum levels in healthy women
No. of Mean + Mean +
women Distributiona Mean s.d. 2 s.d. 3 s.d.
Overall 184 Gaussian 6.7 3.5 13.7 17.2
Premenopausal 61 Gaussian 5.8 2.5 10.8 13.3
Perimenopausalb 47 Gaussian 7.4 3.9 15.2 19.1
Post-menopausal 76 Gaussian 6.9 3.9 14.7 18.6
aDifferences from the Gaussian distribution were assayed by the Kolmogorov-Smirnov
test (P>0.1). bWithin 2 years from their last menstrual period.
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antigen concentration in stage I (median 5.6 U ml', inter-
quartile 4.1-8.4 U ml-) and stage II patients (median
6.2 U ml-', interquartile 4.4-8.4 U ml-') was not
significantly different from the control group (Figure 2).
In patients with breast cancer the antigen level was
significantly higher in post-menopausal (median 7.1, inter-
quartile 5.0-10.5 U ml-') than in premenopausal (median
5.0, interquartile 4.0-8.2 U ml-', P<0.0005). No variations
in CA549 levels were found in relation to histological type,
although a non-significant trend towards higher levels was
found in medullary carcinoma, as previously found for MCA
and CA15.3 (Bombardieri et al., 1989; Gion et al., 1991). No
association was found between CA549 and both ER and PR
when comparing steroid receptors with CA549 as both con-
tinuous variables and categorised using several cut-off points
(5, 10, 20 and 50 fmolpermg of cytosol protein).
CA549 and tumour burden CA549 was significantly associ-
ated with both tumour size and nodal status (Table II). In
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the case of tumour size the concentrations of CA549 were
significantly different between tumours larger than 5 cm and
both those smaller than 2 cm (P = 0.008) and those sized
between 2 and 5 cm (P = 0.010). With regard to the number
of positive lymph nodes, the antigen concentration was
significantly higher in patients with more than three positive
lymph nodes than in those with no positive lymph nodes
(P<0.001) and in those with 1-3 positive lymph nodes
(P<0.001).
The same relation with nodal status was found when con-
sidering only patients with more than ten lymph nodes
examined, in which axillary status should be considered
reliably assessed (data not shown).
As previously shown for MCA and CA15.3 (Bombardieri
et al., 1989; Gion et al., 1991), CA549 failed to distinguish
minor differences in tumour extension (i.e. tumours <2 cm vs
tumours sized 2-5 cm and/or zero vs 1-3 positive lymph
nodes).
Relation between CA549, CA15.3 and MCA A significant
linear correlation was found between CA549 and both
CA15.3 (Figure 3) and MCA (Figure 4). The association
between CA549 and MCA was closer than that between
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Figure 2 CA549 distribution in healthy subjects and in patients
subdivided according to stage. Thin vertical bars = minimum and
maximum values; thick vertical bars = interquartile values;
horizontal bar = median value.
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Figure 3 Correlation between CA549 and CA15.3 serum levels
in patients with primary breast cancer (CA15.3 = 1.6
CA549 + 8.4, r = 0.696, n = 235).
Table II CA549 in primary breast cancer: relationship with tumour
burden
No. of
patients Median Interquartile Min-max
Tumour diameter (cm)
<2 117 6.7 4.7-8.8 1.6-22.8
2-5 110 6.8 4.4-9.4 0.5-31.9
>5 10 14.7 7.5-25.9 5.8-29.5
Number of positive
lymph nodes
0 86 6.2 4.5-8.5 1.8-16.6
1-3 43 5.8 3.9-7.4 0.5-31.9
>3 36 7.8 5.6-11.3 2.2-22.6
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Table III Concordance rate between CA549, CAl5.3 and MCA in primary
breast cancer
CA15.3- CA15.3+ MCA- MCA+
CA549- 171 (72.7%) 48 (20.4%) 186 (89.5%) 7 (3.4%)
CA549+ 0 16 (6.8%) 6 (2.9%) 9 (4.3%)
+, cut-off point for the three markers: 95th percentile values found in the
healthy control group (14 U ml-' for CA549, 25 Uml-' for CA15.3,
17Uml-' for MCA).
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Figure 4 Correlation between CA549 and M
patients with primary breast cancer (MCA
r = 0.808, n = 208).
CA549 and CA15.3. The concordance ra
and both CA15.3 and MCA is summarise
three markers were assayed in the same si
patients and controls, and the 95th percer
healthy subjects was used as the positi
point for all the markers, which was 141
25 Umlh
' for CA15.3 and 17 U ml-' for
concordance is 93.7% between CA549 an(
between CA549 and CA15.3. This latter f
to the number of CA549-negative and CA
found in the present study.
We examined the axillary nodal status i
in whom CA549 and CA15.3 were discor
out of 48 patients were N- and 25 were
were not significantly different between
patients.
Discussion
Serum tumour markers are widely used
breast cancer, although their effectiven
debate. The majority of authors agree
tumour markers are useful since:
1. elevated tumour marker levels almos
an advanced stage in assessing the di
the treatment of the primary tumou
2. marker levels are an early indicator of the success or
failure oftherapy in the monitoring of the treatment for
metastatic breast cancer.
Conversely, despite the huge number of tumour marker
assays carried out during the follow-up of patients without
evidence of disease, their real clinical usefulness is still con-
troversial since the early detection and treatment of meta-
static disease does not improve patient survival significantly
(Ciatto et al., 1985; Zwaveling et al., 1987; Stierer et al.,
1989). Therefore, it is advisable to restrict the number of
tumour markers routinely used until more reliable, dynamic
decision criteria are available (von Kleist et al., 1983; Brown-
ing et al., 1990; Gion, 1992). The problem is of relevance in
the case of the use of mucin-like associated antigens. In
clinical practice the few studies which carried out a com-
parison between mucin-associated tumour markers reported
partly conflicting results (Bombardieri et al., 1989; Barak et
al., 1990; Yerna et al., 1990; Bieglmayer et al., 1991; Dnist-
rian et al., 1991; Miserez et al., 1991; Cazin et al., 1992).
Dnistrian et al. (1991) showed that the combination of
CAM26, CAM29 and CA15.3 is more effective in reflecting
disease status than individual tests. However, they did not
take into account the cost-effectiveness of the strategy they
suggest. On the other hand, Cazin et al. (1992), who
evaluated CA549 and CA15.3, showed that the combination
of the two tests does not provide any more information than
_______ a single test. In current clinical practice several tumour-
25 30 35 associated mucins are frequently measured with the aim of
obtaining more information.
In the present study we assayed CA549 in serum samples
ICA serum levels in from breast cancer and normal subjects comparing the results
= 0.95 CA549 + 2.3, with those of CA15.3 and MCA which were available in the
same samples. To our knowledge the three markers have not
yet been compared in the same patients. CA549 showed
several relationships with biological parameters which are
similar to those found for CA15.3 and MCA. Namely,
Lte between CA549 CA549 showed a trend towards higher levels in older
d in Table III. The patients. The marker was significantly higher in patients with
,erum samples from more advanced disease, but it did not distinguish between
ntile value found in limited differences of tumour burden (i.e. between 1-3 and
ive/negative cut-off zero positive lymph nodes or between tumours sized less than
Uml-' for CA549, 2cm and 2-5 cm). With other evaluated mucin markers,
MCA. The overall CA549 is a 'coarse' detector of tumour spread, probably
d MCA and 79.5% because of factors such as dilution in the bloodstream and
1gure is mainly due divergence between metabolism and production of the mucin
k15.3-positive cases when tumour mass is small.
The correlation between CA549 and MCA was very good,
in these 48 patients with the discordance rate being very limited. The correlation
*dant. Twenty-three between CA549 and CA15.3 was good, but a number of
N+. CA15.3 levels patients showed discordant results depending on the cut-off
these N+ and N- point. Thus 20.4% of cancer patients were CA15.3 positive
and CA549 negative. Since CA15.3 was not significantly
different between N- and N+ patients in this subgroup of
patients, it is equally possible that CA549 does not recognise
N+ patients correctly identified by CA15.3 or that CA549
classifies more correctly than CA15.3 tumours without axil-
I in patients with lary metastasis. Follow-up studies should clarify this
less is still under point.
on the fact that From the results of the present investigation concerning
primary breast cancer we can draw the following con-
t certainly indicate clusions:
isease extent before 1. The commercially available kits evaluated for CA549
ir; determination showed satisfactory performance charac-
a
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teristics for routine use. Moreover, results obtained by
EIA and IRMA kits are interchangeable.
2. CA549 and MCA are highly correlated and their
association should not provide additional information.
Nevertheless, they can behave differently in individual
patients and therefore should not be considered inter-
changeable.
3. CA549 and CA15.3 are well correlated. However, in a
significant number of cases they give discordant inform-
ation. Longitudinal studies are needed to verify if the
association between the two markers may provide a
positive cost-effectiveness ratio in the different clinical
settings in which these markers are used in breast
cancer;
4 The available data do not indicate which of the markers
is superior.
5. The three evaluated mucin markers are not inter-
changeable in individual patients. Therefore, if a patient
is monitored with a marker she should be followed up
with the same marker. As an alternative, when deciding
to change the marker routinely used, the new and the
old mucin markers could be assayed side by side for a
time, until a new baseline is established with the new
marker, before discontinuing the old one.
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